Early-Stage Rehabilitation Trial Underway
Barcelona's Vall d'Hebron University Hospital is leading a clinical trial to evaluate the effectiveness of a portable robotic exoskeleton in the early rehabilitation of traumatic spinal cord injuries. The study, conducted in collaboration with the National Hospital for Paraplegics in Toledo and the University of Lleida, is the first to test this technology during the acute and subacute phases of recovery, within the first six months after injury, when the nervous system is still adapting. The trial uses a device developed by Catalan company ABLE Human Motion, a spin-off of Universitat Politècnica de Catalunya (UPC). Unlike traditional robotic gait systems, which weigh over 30 kilograms and take more than 20 minutes to adjust between patients, the ABLE exoskeleton is significantly lighter, quicker to fit, and allows for personalised assistance levels. This enables more intensive and tailored therapy sessions, crucial when patient fatigue is a limiting factor.
Measuring Broader Health Benefits
While previous research has focused on chronic spinal injury patients, this study targets individuals in the critical early window of recovery. The goal, according to Dr Lluïsa Montesinos, head of the Spinal Cord Injury Unit at Vall d'Hebron and a researcher at the Vall d'Hebron Research Institute (VHIR), is twofold: to assess both the clinical and biomechanical benefits of the device, and to determine the practical efficiency of introducing robotic therapy so soon after injury. The research goes beyond mobility, examining how early upright movement impacts cardiovascular and circulatory function, digestive health, joint mobility, muscle tone, and bone density, a key factor in preventing immobility-related osteoporosis.
15 Patients Enrolled, Results Expected by 2028
Fifteen volunteer patients are currently enrolled, five at Vall d'Hebron and ten at the Toledo hospital, and will be monitored for one year. The University of Lleida is conducting a parallel analysis of the economic impact of integrating this therapy into Spain's public health system during the acute rehabilitation phase. The project was announced in mid-November 2026 and is now actively collecting data. Final conclusions are expected to be published in 2028. The ABLE exoskeleton may also benefit patients with complete spinal injuries (C7-L5), potentially improving tissue oxygenation and reducing pressure ulcer risks.
Sources: CatalunyaPress, iris.upc.edu, vallhebron.com, castillalamancha.es.